Payment overview · 2025
General Payments
$923.76
55 reported records · 14 companies
Healthcare provider profile · identity verified
Mohsin M Syed, MD
Allopathic & Osteopathic Physicians|General Practice · NEW HARTFORD, NY · NPI 1437291689
Verified facts
What the public records show
CMS Open Payments records show Mohsin M Syed, MD received $923.76 in general payments during 2025 across 55 reported records.
ABBVIE INC. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brixadi, Creon, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Braeburn Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRIXADI as an associated drug or biological on 15883 records involving 5757 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brixadi by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $259.19 | 28.1% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.64 | 17.2% | 12 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $87.11 | 9.4% | 4 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $77.47 | 8.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.03 | 7.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.70 | 6.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.43 | 5.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.08 | 3.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.85 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.17 | 2.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.16 | 2.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.17 | 2.2% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $19.26 | 2.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.50 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $923.76 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $158.64 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $158.64 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $152.98 | 9 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $77.47 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.97 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.97 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $47.03 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.73 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $27.19 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $10.05 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRIXADI brixadi |
2025 | Brixadi | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 225 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Braeburn Inc. Exact reporting entity; no affiliate inference |
2025 | BRIXADI open payments reported associated product |
CMS Open Payments — General Payments 15883 supporting records · 5757 recipient NPIs · example record 1249056386 |
Brixadi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
95 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
225 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1014 | 351 |
| Lisinopril | Lisinopril | 494 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 164 |
| Omeprazole | Omeprazole | 444 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 434 | 148 |
| Gabapentin | Gabapentin | 399 | 138 |
| Metformin Hcl Er | Metformin Hcl | 349 | 105 |
| Losartan Potassium | Losartan Potassium | 331 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 320 | 112 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 313 | 109 |
| Metformin Hcl | Metformin Hcl | 306 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 90 |
| Furosemide | Furosemide | 279 | 102 |
| Pregabalin | Pregabalin | 271 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 250 | 93 |
| Ozempic | Semaglutide | 225 | 41 |
| Sertraline Hcl | Sertraline Hcl | 224 | 62 |
| Montelukast Sodium | Montelukast Sodium | 208 | 70 |
| Eliquis | Apixaban | 200 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 73 |
| Potassium Chloride | Potassium Chloride | 193 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 63 |
| Famotidine | Famotidine | 179 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 57 |
| Simvastatin | Simvastatin | 165 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 62 |
| Trazodone Hcl | Trazodone Hcl | 152 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 144 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 140 | 44 |
| Jardiance | Empagliflozin | 140 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 138 | 24 |
| Meloxicam | Meloxicam | 134 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 127 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 35 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 115 | 35 |
| Clonidine Hcl | Clonidine Hcl | 114 | 35 |
| Topiramate | Topiramate | 112 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 39 |
| Clonazepam | Clonazepam | 108 | 27 |
| Glimepiride | Glimepiride | 106 | 39 |
| Ezetimibe | Ezetimibe | 98 | 31 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 96 | 29 |
| Xarelto | Rivaroxaban | 95 | 32 |
| Prednisone | Prednisone | 94 | 75 |
| Carvedilol | Carvedilol | 89 | 35 |
| Spironolactone | Spironolactone | 89 | 36 |
| Januvia | Sitagliptin Phosphate | 88 | 30 |
| Alprazolam | Alprazolam | 83 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 45 |
| Ibuprofen | Ibuprofen | 81 | 37 |
| Farxiga | Dapagliflozin Propanediol | 80 | 25 |
| Ramipril | Ramipril | 79 | 24 |
| Donepezil Hcl | Donepezil Hcl | 78 | 28 |
| Buspirone Hcl | Buspirone Hcl | 77 | 28 |
| Atenolol | Atenolol | 71 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 26 |
| Finasteride | Finasteride | 64 | 20 |
| Glipizide | Glipizide | 64 | 23 |
| Glipizide Er | Glipizide | 61 | 19 |
| Tramadol Hcl | Tramadol Hcl | 61 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 18 |
| Alendronate Sodium | Alendronate Sodium | 59 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 22 |
| Allopurinol | Allopurinol | 51 | 25 |
| Torsemide | Torsemide | 51 | 21 |
| Bupropion Xl | Bupropion Hcl | 50 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 13 |
| Buprenorphine Hcl | Buprenorphine Hcl | 45 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 17 |
| Mupirocin | Mupirocin | 41 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 16 |
| Buprenorphine | Buprenorphine | 39 | 13 |
| Linzess | Linaclotide | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 15 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 38 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 14 |
| Irbesartan | Irbesartan | 37 | 11 |
| Naproxen | Naproxen | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Memantine Hcl | Memantine Hcl | 33 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | 12 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | 12 |
| Sucralfate | Sucralfate | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 29 | 11 |
| Nystatin | Nystatin | 29 | 18 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 25 |
| Levetiracetam | Levetiracetam | 27 | 11 |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 16 |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | 12 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Etodolac | Etodolac | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Brixadi | Buprenorphine | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $923.76 · 55 records | ABBVIE INC. | BRIXADI, CAPLYTA, CAPVAXIVE, CREON, GARDASIL 9, GEMTESA, INJECTAFER, JARDIANCE, Kerendia, LINZESS, MAVYRET, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brixadi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error